Anti PD-1 (nivolumab, pembrolizumab) or anti PD-L1 (atezolizumab) versus docetaxel for previously treated patients with advanced NSCLC: A meta-analysis - Des Guetz, G (J Clin Oncol, 2016)
(suppl; abstr e20555)